Molecular classification of breast cancer

Breast cancer is a complex, multifaceted disease encompassing a great variety of entities that show considerable variation in clinical, morphological and molecular attributes. Traditional classifications including histological assessment and clinical staging are used to guide patient management. In recent years, there has been exponential progress in molecular analysis with profound implications for our understanding of breast cancer biology and, hence, classification. There are now genome-based frameworks for the molecular categorisation of breast cancer including the development of prognostic and predictive signatures that potentially allow individualisation of treatment. Here we review the current state of the molecular classifications of in situ and invasive breast cancer including special subtypes. Future perspectives are also provided.

[1]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Jack Cuzick,et al.  Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Thompson,et al.  Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS) , 2010, Breast Cancer Research.

[4]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[5]  J. Haerting,et al.  Gene-expression signatures in breast cancer. , 2003, The New England journal of medicine.

[6]  William C Hahn,et al.  Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. , 2009, Cancer cell.

[7]  P. Sorensen,et al.  Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. , 2002, Cancer cell.

[8]  Thomas Bachelot,et al.  Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). , 2014, The Lancet. Oncology.

[9]  Karla Kerlikowske,et al.  Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. , 2007, Cancer cell.

[10]  A. Børresen-Dale,et al.  Mutational Processes Molding the Genomes of 21 Breast Cancers , 2012, Cell.

[11]  H. Schwarzenbach Circulating nucleic acids as biomarkers in breast cancer , 2013, Breast Cancer Research.

[12]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[13]  B. Shapiro,et al.  Free DNA in the serum of cancer patients and the effect of therapy. , 1977, Cancer research.

[14]  J. Reis-Filho,et al.  Breast cancer precursors revisited: molecular features and progression pathways , 2010, Histopathology.

[15]  Emad A. Rakha,et al.  Combinatorial biomarker expression in breast cancer , 2010, Breast Cancer Research and Treatment.

[16]  W. McGuire,et al.  Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. , 1978, Endocrinology.

[17]  V. Jordan,et al.  The estrogen receptor: a model for molecular medicine. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  A. Ashworth,et al.  Mixed micropapillary–ductal carcinomas of the breast: a genomic and immunohistochemical analysis of morphologically distinct components , 2009, The Journal of pathology.

[19]  M. Fernö,et al.  Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels , 2004, Breast Cancer Research and Treatment.

[20]  Alex M. Fichtenholtz,et al.  Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.

[21]  Robin L. Jones,et al.  Genomic profile of a secretory breast cancer with an ETV6–NTRK3 duplication , 2009, Journal of Clinical Pathology.

[22]  M. Stratton,et al.  Deciphering Signatures of Mutational Processes Operative in Human Cancer , 2013, Cell reports.

[23]  Päivi Heikkilä,et al.  Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies , 2010, PLoS medicine.

[24]  M. Gilcrease,et al.  Ki-67 as Prognostic Marker in Early Breast Cancer: A Meta-analysis of Published Studies Involving 12 155 Patients , 2008 .

[25]  S. Devries,et al.  Invasive micropapillary carcinoma of the breast is associated with chromosome 8 abnormalities detected by comparative genomic hybridization. , 2002, Human pathology.

[26]  Jorge S. Reis-Filho,et al.  Going with the Flow: From Circulating Tumor Cells to DNA , 2013, Science Translational Medicine.

[27]  D. Easton,et al.  Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival , 2007, Breast Cancer Research.

[28]  I. Ellis,et al.  Modern Classification of Breast Cancer: Should we Stick With Morphology or Convert to Molecular Profile Characteristics , 2011, Advances in anatomic pathology.

[29]  G. Azabdaftari,et al.  Refinement of breast cancer classification by molecular characterization of histological special types , 2009 .

[30]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[31]  Thomas J. Smith,et al.  Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[33]  B. Kreike,et al.  The molecular underpinning of lobular histological growth pattern: a genome‐wide transcriptomic analysis of invasive lobular carcinomas and grade‐ and molecular subtype‐matched invasive ductal carcinomas of no special type , 2010, The Journal of pathology.

[34]  Jorge S Reis-Filho,et al.  The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade , 2010, The Journal of pathology.

[35]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[36]  Päivikki Kauraniemi,et al.  Amplification of a 280-kilobase core region at the ERBB2 locus leads to activation of two hypothetical proteins in breast cancer. , 2003, The American journal of pathology.

[37]  P. O’Connell,et al.  Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. , 1998, Journal of the National Cancer Institute.

[38]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  C. Perou,et al.  Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma , 2006, Modern Pathology.

[40]  Ian O Ellis,et al.  Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[42]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[43]  I. Ellis,et al.  Pleomorphic lobular carcinoma of the breast: is it a prognostically significant pathological subtype independent of histological grade? , 2013, Modern Pathology.

[44]  A. Vincent-Salomon,et al.  Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrum , 2009, Modern Pathology.

[45]  Charles M. Perou,et al.  Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.

[46]  Shu Ichihara,et al.  Breast cancer prognostic classification in the molecular era: the role of histological grade , 2010, Breast Cancer Research.

[47]  O. Dietze,et al.  Chromogenic In Situ Hybridization: A Novel Approach to a Practical and Sensitive Method for the Detection of HER2 Oncogene in Archival Human Breast Carcinoma , 2002, Laboratory Investigation.

[48]  A. Schäffer,et al.  Tumorigenesis and Neoplastic Progression Single-Cell Genetic Analysis of Ductal Carcinoma in Situ and Invasive Breast Cancer Reveals Enormous Tumor Heterogeneity yet Conserved Genomic Imbalances and Gain of MYC during Progression , 2012 .

[49]  Roman Rouzier,et al.  Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.

[50]  G. Ball,et al.  Reading the prognosis of the individual with breast cancer. , 2007, European journal of cancer.

[51]  Joshua F. McMichael,et al.  Whole Genome Analysis Informs Breast Cancer Response to Aromatase Inhibition , 2012, Nature.

[52]  S. Devries,et al.  Patterns of Chromosomal Alterations in Breast Ductal Carcinoma In situ , 2004, Clinical Cancer Research.

[53]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[54]  A. Ashworth,et al.  Basal-like breast carcinomas: clinical outcome and response to chemotherapy , 2006, Journal of Clinical Pathology.

[55]  Irmtraud M. Meyer,et al.  The clonal and mutational evolution spectrum of primary triple-negative breast cancers , 2012, Nature.

[56]  D. Easton,et al.  Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast , 2006, Histopathology.

[57]  Nilanjan Chatterjee,et al.  Estrogen Receptor Breast Cancer Phenotypes in the Surveillance, Epidemiology, and End Results Database , 2002, Breast Cancer Research and Treatment.

[58]  Karla Kerlikowske,et al.  Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. , 2010, Journal of the National Cancer Institute.

[59]  S. Lakhani,et al.  Molecular evolution of breast cancer , 2005, The Journal of pathology.

[60]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[61]  Sunil R Lakhani,et al.  The molecular genetics of breast cancer: the contribution of comparative genomic hybridization. , 2005, Pathology, research and practice.

[62]  A. Goldhirsch,et al.  Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer. , 2012, Clinical breast cancer.

[63]  Ajay N. Jain,et al.  Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. , 2006, Cancer cell.

[64]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[65]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[66]  W. McGuire,et al.  Specific progesterone receptors in human breast cancer , 1975, Steroids.

[67]  M. Alaoui-Jamali,et al.  Molecular insights on basal-like breast cancer , 2012, Breast Cancer Research and Treatment.

[68]  P. Fortina,et al.  Circulating tumor DNA to monitor metastatic breast cancer. , 2013, The New England journal of medicine.

[69]  Karen Gelmon,et al.  Metastatic behavior of breast cancer subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  J. Bergh,et al.  Identification of molecular apocrine breast tumours by microarray analysis , 2005, Breast Cancer Research.

[71]  A. Ashworth,et al.  Breast cancer molecular profiling with single sample predictors: a retrospective analysis. , 2010, The Lancet. Oncology.

[72]  J. Cuzick,et al.  Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  A. Nobel,et al.  The molecular portraits of breast tumors are conserved across microarray platforms , 2006, BMC Genomics.

[74]  A. Børresen-Dale,et al.  The landscape of cancer genes and mutational processes in breast cancer , 2012, Nature.

[75]  C. Poremba,et al.  Comparative genomic hybridization of ductal carcinoma in situ of the breast—evidence of multiple genetic pathways , 1999, The Journal of pathology.

[76]  J. Polman,et al.  ER beta: identification and characterization of a novel human estrogen receptor. , 1996, FEBS letters.

[77]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[78]  F. Bertucci,et al.  A refined molecular taxonomy of breast cancer , 2011, Oncogene.

[79]  V. Tsikitis,et al.  Biology of Ductal Carcinoma in Situ Classification Based on Biologic Potential , 2006, American journal of clinical oncology.

[80]  P. Ravdin,et al.  Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  A. Ashworth,et al.  Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas , 2008, The Journal of pathology.

[82]  R. Greil,et al.  Circulating tumor DNA to monitor metastatic breast cancer. , 2013, The New England journal of medicine.

[83]  C. Osborne,et al.  Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  T. Sørlie,et al.  Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study , 2013, BMC Cancer.

[85]  Daniel Pinkel,et al.  Genomic microarrays in human genetic disease and cancer. , 2003, Human molecular genetics.

[86]  Johan Staaf,et al.  Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  G. Parmigiani,et al.  Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome Sequencing , 2012, Science Translational Medicine.

[88]  Steven A. Roberts,et al.  An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers , 2013, Nature Genetics.

[89]  P. Stephens,et al.  A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice. , 2014, The oncologist.

[90]  J. Polman,et al.  ERβ: Identification and characterization of a novel human estrogen receptor , 1996 .

[91]  Shu Ichihara,et al.  Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists , 2011, Modern Pathology.

[92]  A. Børresen-Dale,et al.  COMPLEX LANDSCAPES OF SOMATIC REARRANGEMENT IN HUMAN BREAST CANCER GENOMES , 2009, Nature.

[93]  R. Vierkant,et al.  p16INK4a Expression and Breast Cancer Risk in Women with Atypical Hyperplasia , 2011, Cancer Prevention Research.

[94]  G. Ball,et al.  Identification of key clinical phenotypes of breast cancer using a reduced panel of protein biomarkers , 2013, British Journal of Cancer.

[95]  L. Pusztai,et al.  Gene expression profiling in breast cancer: classification, prognostication, and prediction , 2011, The Lancet.

[96]  Michael L. Gatza,et al.  A pathway-based classification of human breast cancer , 2010, Proceedings of the National Academy of Sciences.

[97]  안성민 Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing , 2011 .

[98]  Adrian V. Lee,et al.  Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. , 2005, Journal of the National Cancer Institute.

[99]  P. Kauraniemi,et al.  Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer. , 2006, Endocrine-related cancer.

[100]  J. Thiery,et al.  Integrated Genomic and Transcriptomic Analysis of Ductal Carcinoma In situ of the Breast , 2008, Clinical Cancer Research.

[101]  H. Bloom,et al.  Histological Grading and Prognosis in Breast Cancer , 1957, British Journal of Cancer.

[102]  A. Vincent-Salomon,et al.  Lobular invasive carcinoma of the breast is a molecular entity distinct from luminal invasive ductal carcinoma. , 2010, European journal of cancer.

[103]  M. J. van de Vijver Molecular tests as prognostic factors in breast cancer. , 2014, Virchows Archiv : an international journal of pathology.

[104]  Kenny Q. Ye,et al.  Novel patterns of genome rearrangement and their association with survival in breast cancer. , 2006, Genome research.

[105]  Jorge S. Reis-Filho,et al.  Histological types of breast cancer: How special are they? , 2010, Molecular oncology.

[106]  A. Molinolo,et al.  The MPA mouse breast cancer model: evidence for a role of progesterone receptors in breast cancer. , 2009, Endocrine-related cancer.

[107]  G. Tse,et al.  Neuroendocrine differentiation in pure type mammary mucinous carcinoma is associated with favorable histologic and immunohistochemical parameters , 2004, Modern Pathology.

[108]  H. Horlings,et al.  Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck , 2009, Proceedings of the National Academy of Sciences.

[109]  Jason I. Herschkowitz,et al.  Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer , 2010, Breast Cancer Research.

[110]  Charles M. Perou,et al.  Ductal Carcinoma In situ and the Emergence of Diversity during Breast Cancer Evolution , 2008, Clinical Cancer Research.

[111]  Charles M. Perou,et al.  Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse , 2011, Breast Cancer Research and Treatment.

[112]  Funda Meric-Bernstam,et al.  Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes , 2013, Clinical Cancer Research.

[113]  Lajos Pusztai,et al.  Molecular classification of breast cancer: limitations and potential. , 2006, The oncologist.